From: Sent: To: Subject:	Holger Link Friday, 8 May 2020 3:27 PM Bell, Simon RE: AA1000486 - Medicines Australia and Generic and Biosimilar Medicines Association interim authorisation - Request for information [SEC=OFFICIAL] [ACCC-ACCCANDAER.FID2548316]
Dear Simon,	
I hope my email fir	nds you well.
Thank you very mu to your questions b	uch for reaching out in regards to the Interim Authorisation AA1000486. Please find my responses pelow:
•	Conduct working as expected? I had two initial meetings (for 2 different molecules) so far that and the Department of Health and in regards to the conduct everything went according to
	Conduct taking place as described in the application and the interim authorisation decision? Yes, mpanies were sharing information and views in accordance to the proposed conduct.
Are there any pa insight into the sup	rticular benefits or detriments that the Proposed Conduct is resulting in? It is important to get oply and demand situation for the entire country beyond an individual company's situation to gaps and to adjust accordingly. It was therefore very valuable to understand the situation across
why not? We have	ation engaged in the Proposed Conduct, and if so, what was your experience in doing so? If not, actively engaged in sharing the company's current situation, experiences and potential pain the requirements of the conduct) and shared thoughts on moving forward. The feedback and the ry good.
_	need to be seen as a start and I see value in continuing with the work group to regularly monitor o ensure uninterrupted supplies of critical lines.
Please let me know	v in case you need any further information.
Stay safe	
Kind regards Holger	
Dr. Holger Link Business Manager Pain Therapy, Pha	Hospital Care rmaceuticals, OEM & Export
B. Braun Australia Level 5, 7-9 Irvine	

Mobile:

Web: http://www.bbraun.com.au

Bella Vista NSW 2153

Direct: Fax: